Specificity
BTE 002-08 is specific for native human PICP.
Immunogen
PICP purified from second-trimester amniotic fluid by affinity chromatography.
Positive Species Reactivity
Human
Negative Species Reactivity
Not determined
Epitope Specificity
Epitope differs from that of BTE 002-08
Unit Size
200 µL: Cat. No. BTE 002-18-021 mL: Cat. No. BTE 002-18-11 mg/mL +/- 15%. See Certificate of Analysis for details.
Purification
protein A/G purified (from culture supernatant)
Solvent
0.01 M phosphate buffer, pH 7.4, containing 0.5 M NaCl and 15 mM sodium azide
Conjugation
Unconjugated BSA free
Storage
4-8ºC without exposure to light. No precautions necessary during handling.
Target
Type I collagen is present in connective tissue and bone where it makes up about 90% of the organic matrix. Type I collagen is produced from type-I procollagen by the proteolytic cleavage of N- and C-telopeptides, which are released into the circulation. The propeptides can be measured in serum as markers of the production of trype-I collagen. Elevated values of these propeptides are found in serum from patients with various metabolic or malignant bone diseases. Procollagen type I C-terminal propeptide (PICP) has a molecular mass of approximately 100 kDa. Its normal concentration in serum depends on age and sex.
